Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (331-340 of 342) with videos related to

Pageof 35
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 26, 2023
Sars-CoV2 infection in pregnant women with multiple sclerosisMaria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neuroimmunology|August 29, 2006
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans, Maria Ban, David Booth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
European Journal of Neurology|May 18, 2022
Confirmed disability progression as a marker of permanent disability in multiple sclerosisSifat Sharmin, Francesca Bovis, Charles Malpas, et al.
Journal of Neurology|December 22, 2023
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS RegistryPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Journal of Immunological Methods|October 28, 2009
Neurofilament ELISA validationAxel Petzold, Ayse Altintas, Laura Andreoni, et al.
JAMA Network Open|November 3, 2025
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MSShalom Haggiag, Luca Prosperini, Massimo Filippi, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Pageof 35

Showing results (331-340 of 342) with videos related to

Sort By:
Pageof 35
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 26, 2023
Sars-CoV2 infection in pregnant women with multiple sclerosisMaria Grazia Aprea, Irene Schiavetti, Emilio Portaccio, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Journal of Neuroimmunology|August 29, 2006
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans, Maria Ban, David Booth, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
European Journal of Neurology|May 18, 2022
Confirmed disability progression as a marker of permanent disability in multiple sclerosisSifat Sharmin, Francesca Bovis, Charles Malpas, et al.
Journal of Neurology|December 22, 2023
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS RegistryPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
Journal of Immunological Methods|October 28, 2009
Neurofilament ELISA validationAxel Petzold, Ayse Altintas, Laura Andreoni, et al.
JAMA Network Open|November 3, 2025
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MSShalom Haggiag, Luca Prosperini, Massimo Filippi, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Pageof 35